Saturday, 31 October 2026European Markets

ARRIBATEC GROUP Stock Jumps By 28% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ARRIBATEC GROUP (Oslo Børs Benchmark Index_GI: ARR.OL) rose by a staggering 28.6% in 21 sessions from kr4.86 to kr6.25 at 17:24 EST on Monday, after four sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI is dropping 1.13% to kr1,231.97, following the last session's upward trend.

About ARRIBATEC GROUP

Arribatec Group ASA, a software and consulting company, provides digital business solutions in Norway, Europe, the Americas, and internationally. The company offers solutions for businesses, including ERP systems, integrations, consulting, health checks, develops, HR and payroll, financial and project planning, bank solutions, and travel and expenses. Its solutions include QualiWare, a management system that structures and visualizes processes, activities, regulations, and requirements; Unit4 solutions; RamBase, an ERP business solution that gives control over the value chain; Power BI solutions; Hypergene, a business management tool; Adra Suite that integrates with other financial systems; Microsoft 365; CatalystOne; and Pagero that ensures compliance with legal and electronic billing requirements. The company was incorporated in 1998 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ARRIBATEC GROUP has a trailing twelve months EPS of kr-1.36.

More news about ARRIBATEC GROUP (ARR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com